EP2812355A4 - COMPOSITIONS AND METHODS OF USING CSF1R INHIBITORS - Google Patents

COMPOSITIONS AND METHODS OF USING CSF1R INHIBITORS

Info

Publication number: EP2812355A4
Authority: EP; European Patent Office
Prior art keywords: compositions; methods; csf1r inhibitors; csf1r; inhibitors
Prior art date: 2012-02-06
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP13746304.8A

Other languages

German (de)

French (fr)

Other versions

EP2812355A1 (en

Inventor

Xiaolei Ma

Yongmei Chen

Scott Stawicki

Yan Wu

Flavius Martin

wei yu Lin

Melissa A Starovasnik

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

F Hoffmann La Roche AG

Original Assignee

F Hoffmann La Roche AG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-02-06

Filing date

2013-02-06

Publication date

2016-03-02

2013-02-06 Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG

2014-12-17 Publication of EP2812355A1 publication Critical patent/EP2812355A1/en

2016-03-02 Publication of EP2812355A4 publication Critical patent/EP2812355A4/en

Status Withdrawn legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7153—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for colony-stimulating factors [CSF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/243—Colony Stimulating Factors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Rheumatology (AREA)
Toxicology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Transplantation (AREA)
Cell Biology (AREA)
Pain & Pain Management (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

EP13746304.8A 2012-02-06 2013-02-06 COMPOSITIONS AND METHODS OF USING CSF1R INHIBITORS Withdrawn EP2812355A4 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201261595658P	2012-02-06	2012-02-06
US201261680674P	2012-08-07	2012-08-07
PCT/US2013/024998 WO2013119716A1 (en)	2012-02-06	2013-02-06	Compositions and methods for using csf1r inhibitors

Publications (2)

Publication Number	Publication Date
EP2812355A1 EP2812355A1 (en)	2014-12-17
EP2812355A4 true EP2812355A4 (en)	2016-03-02

Family

ID=48947977

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP13746304.8A Withdrawn EP2812355A4 (en)	2012-02-06	2013-02-06	COMPOSITIONS AND METHODS OF USING CSF1R INHIBITORS

Country Status (10)

Country	Link
EP (1)	EP2812355A4 (en)
JP (2)	JP6416630B2 (en)
KR (1)	KR20140127855A (en)
CN (1)	CN104093740B (en)
BR (1)	BR112014018961A8 (en)
CA (1)	CA2861122A1 (en)
HK (1)	HK1202879A1 (en)
MX (1)	MX2014008961A (en)
RU (1)	RU2014136332A (en)
WO (1)	WO2013119716A1 (en)

Families Citing this family (220)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SI2949670T1 (en)	2009-12-10	2019-05-31	F. Hoffmann-La Roche Ag	Antibodies binding preferentially human csf1r extracellular domain 4 and their use
US10023643B2 (en)	2011-12-15	2018-07-17	Hoffmann-La Roche Inc.	Antibodies against human CSF-1R and uses thereof
US9546203B2 (en)	2013-03-14	2017-01-17	Amgen Inc.	Aglycosylated Fc-containing polypeptides with cysteine substitutions
AR095882A1 (en)	2013-04-22	2015-11-18	Hoffmann La Roche	ANTIBODY COMBINATION THERAPY AGAINST HUMAN CSF-1R WITH A TLR9 AGONIST
GB201315486D0 (en) *	2013-08-30	2013-10-16	Ucb Pharma Sa	Antibodies
AR097584A1 (en)	2013-09-12	2016-03-23	Hoffmann La Roche	ANTIBODY COMBINATION THERAPY AGAINST HUMAN CSF-1R AND ANTIBODIES AGAINST HUMAN PD-L1
EA201990240A1 (en)	2013-12-24	2019-06-28	Бристол-Маерс Сквибб Компани	NEW TRICYCLIC CONNECTIONS AS ANTICATIVE AGENTS
JP2017525753A (en)	2014-06-06	2017-09-07	フレクサス・バイオサイエンシーズ・インコーポレイテッドＦｌｅｘｕｓＢｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ．	Immunomodulator
KR101923326B1 (en)	2014-06-06	2018-11-29	브리스톨-마이어스 스큅 컴퍼니	Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
US20180113139A1 (en) *	2014-07-28	2018-04-26	Nogra Pharma Limited	Methods and compositions for diagnosing and treating inflammatory bowel disorders
BR112017008809A2 (en)	2014-11-05	2017-12-19	Flexus Biosciences Inc	immunoregulatory agents
UY36390A (en)	2014-11-05	2016-06-01	Flexus Biosciences Inc	MODULATING COMPOUNDS OF INDOLAMINE ENZYME 2,3-DIOXYGENASE (IDO), ITS SYNTHESIS METHODS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AR102537A1 (en)	2014-11-05	2017-03-08	Flexus Biosciences Inc	IMMUNOMODULATING AGENTS
TN2017000203A1 (en)	2014-11-21	2018-10-19	Bristol Myers Squibb Co	Antibodies against cd73 and uses thereof
US10703813B2 (en) *	2014-12-19	2020-07-07	Universite De Nantes	Anti IL-34 antibodies
TW201630907A (en)	2014-12-22	2016-09-01	必治妥美雅史谷比公司	TGF[beta]R antagonists
US10189902B2 (en)	2014-12-23	2019-01-29	Bristol-Myers Squibb Company	Antibodies to TIGIT
JP6490419B2 (en) *	2014-12-24	2019-03-27	学校法人関西医科大学	Regulatory T cell differentiation inducer
US10983128B2 (en)	2015-02-05	2021-04-20	Bristol-Myers Squibb Company	CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy
BR112017017135A2 (en)	2015-03-02	2018-04-03	Rigel Pharmaceuticals, Inc.	tgf-beta inhibitors
AU2016243937A1 (en)	2015-04-03	2017-11-23	Bristol-Myers Squibb Company	Inhibitors of indoleamine 2,3-dioxygenase for the treatment of cancer
WO2016162505A1 (en)	2015-04-08	2016-10-13	F-Star Biotechnology Limited	Her2 binding agent therapies
IL304950A (en)	2015-04-10	2023-10-01	Amgen Inc	Interleukin-2 muteins for the expansion of t-regulatory cells
US10683290B2 (en)	2015-05-11	2020-06-16	Bristol-Myers Squibb Company	Tricyclic compounds as anticancer agents
ES2770349T3 (en)	2015-05-12	2020-07-01	Bristol Myers Squibb Co	5H-pyrido [3,2-b] indole compounds as antineoplastic agents
US10591465B2 (en)	2015-05-12	2020-03-17	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and kits for labeling, detection and isolation of Foxp3+ regulatory T cells, isolated population of Foxp3+ regulatory T cells thus obtained and uses thereof
US9725449B2 (en)	2015-05-12	2017-08-08	Bristol-Myers Squibb Company	Tricyclic compounds as anticancer agents
SG10202002131PA (en)	2015-05-21	2020-05-28	Harpoon Therapeutics Inc	Trispecific binding proteins and methods of use
MX2017014782A (en) *	2015-05-27	2018-02-15	Ucb Biopharma Sprl	Method for the treatment of neurological disease.
JP6797137B2 (en)	2015-05-29	2020-12-09	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	Antibodies to OX40 and its use
WO2016196679A1 (en)	2015-06-02	2016-12-08	Genentech, Inc.	Compositions and methods for using anti-il-34 antibodies to treat neurological diseases
JP6621252B2 (en) *	2015-06-17	2019-12-18	国立大学法人北海道大学	Treatment resistance reducing agent for treatment resistant cancer
CN107922500A (en)	2015-06-29	2018-04-17	洛克菲勒大学	The anti-CD 40 antibodies of agonist activity with enhancing
US10399987B2 (en)	2015-07-28	2019-09-03	Bristol-Myer Squibb Company	TGF beta receptor antagonists
CN108349976A (en)	2015-08-25	2018-07-31	百时美施贵宝公司	TGF β receptor antagonists
JP6951340B2 (en)	2015-09-23	2021-10-20	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	Glypican-3 binding fibronectin-based scaffold molecule
BR112018010172A2 (en)	2015-11-19	2018-11-21	Bristol Myers Squibb Co	antibodies to glucocorticoid-induced tumor necrosis factor receptor (gitr) and their uses
JP6856648B2 (en)	2015-12-15	2021-04-07	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	CXCR4 receptor antagonist
SG11201806861SA (en)	2016-03-04	2018-09-27	Bristol Myers Squibb Co	Combination therapy with anti-cd73 antibodies
JP7038064B2 (en)	2016-04-18	2022-03-17	セルデックスセラピューティクスインコーポレイテッド	Agonist antibody that binds to human CD40 and its use
CN109311816A (en)	2016-05-04	2019-02-05	百时美施贵宝公司	The inhibitor and its application method of indole amine 2,3-dioxygenase
JP2019516681A (en)	2016-05-04	2019-06-20	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	Indoleamine 2,3-dioxygenase inhibitors and methods of use thereof
CN109414421A (en)	2016-05-04	2019-03-01	百时美施贵宝公司	The inhibitor and its application method of indole amine 2,3-dioxygenase
JP2019519485A (en)	2016-05-04	2019-07-11	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	Indoleamine 2,3-dioxygenase inhibitors and methods of use thereof
WO2017192811A1 (en)	2016-05-04	2017-11-09	Bristol-Myers Squibb Company	Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US11623958B2 (en)	2016-05-20	2023-04-11	Harpoon Therapeutics, Inc.	Single chain variable fragment CD3 binding proteins
US10994033B2 (en)	2016-06-01	2021-05-04	Bristol-Myers Squibb Company	Imaging methods using 18F-radiolabeled biologics
MY200602A (en)	2016-07-14	2024-01-04	Bristol Myers Squibb Co	Antibodies against tim3 and uses thereof
WO2018017633A1 (en)	2016-07-21	2018-01-25	Bristol-Myers Squibb Company	TGF Beta RECEPTOR ANTAGONISTS
EP3504239B1 (en)	2016-08-25	2024-05-29	F. Hoffmann-La Roche AG	Intermittent dosing of an anti-csf-1r antibody in combination with macrophage activating agent
KR20190040502A (en)	2016-08-26	2019-04-18	브리스톨-마이어스 스큅 컴퍼니	Inhibitors of indoleamine 2,3-dioxygenase and methods of use thereof
CN109843322A (en)	2016-08-26	2019-06-04	百时美施贵宝公司	The inhibitor and its application method of indole amine 2,3-dioxygenase
US10660909B2 (en)	2016-11-17	2020-05-26	Syntrix Biosystems Inc.	Method for treating cancer using chemokine antagonists
CN110072553B (en)	2016-12-22	2023-09-15	豪夫迈·罗氏有限公司	Treatment of tumors with anti-CSF-1R antibodies in combination with anti-PD-L1 antibodies after failure of anti-PD-L1/PD 1 treatment
US10961239B2 (en)	2017-01-05	2021-03-30	Bristol-Myers Squibb Company	TGF beta receptor antagonists
HRP20231157T1 (en)	2017-01-20	2024-01-05	Arcus Biosciences, Inc.	Azolopyrimidine for the treatment of cancer-related disorders
TWI788340B (en)	2017-04-07	2023-01-01	美商必治妥美雅史谷比公司	Anti-icos agonist antibodies and uses thereof
BR112019021992A2 (en)	2017-04-21	2020-06-09	Kyn Therapeutics	indole ahr inhibitors and uses thereof
US11066392B2 (en)	2017-05-12	2021-07-20	Bristol-Myers Squibb Company	Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
AU2018265856B2 (en)	2017-05-12	2023-04-27	Harpoon Therapeutics, Inc.	Mesothelin binding proteins
US11220492B2 (en)	2017-05-17	2022-01-11	Arcus Biosciences, Inc.	Quinazoline-pyrazole derivatives for the treatment of cancer-related disorders
JP7537874B2 (en)	2017-05-19	2024-08-21	シンダックスファーマシューティカルズ，インコーポレイテッド	Combination therapy
EP3644993B1 (en)	2017-06-30	2023-08-02	Bristol-Myers Squibb Company	Amorphous and crystalline forms of ido inhibitors
ES2932354T3 (en)	2017-07-28	2023-01-18	Bristol Myers Squibb Co	Cyclic dinucleotides as anticancer agents
EP3661948B1 (en)	2017-08-04	2022-06-01	BicycleTx Limited	Bicyclic peptide ligands specific for cd137
JP7269917B2 (en)	2017-08-17	2023-05-09	イケナオンコロジー，インコーポレイテッド	AHR inhibitors and uses thereof
JP7208225B2 (en)	2017-08-31	2023-01-18	ブリストル－マイヤーズスクイブカンパニー	Cyclic dinucleotides as anticancer agents
WO2019046496A1 (en)	2017-08-31	2019-03-07	Bristol-Myers Squibb Company	Cyclic dinucleotides as anticancer agents
KR102651946B1 (en)	2017-08-31	2024-03-26	브리스톨-마이어스 스큅 컴퍼니	Cyclic dinucleotides as anticancer agents
US11358948B2 (en)	2017-09-22	2022-06-14	Kymera Therapeutics, Inc.	CRBN ligands and uses thereof
US11623932B2 (en)	2017-09-22	2023-04-11	Kymera Therapeutics, Inc.	Protein degraders and uses thereof
US11203592B2 (en)	2017-10-09	2021-12-21	Bristol-Myers Squibb Company	Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2019074822A1 (en)	2017-10-09	2019-04-18	Bristol-Myers Squibb Company	Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2019075090A1 (en)	2017-10-10	2019-04-18	Tilos Therapeutics, Inc.	Anti-lap antibodies and uses thereof
US11660311B2 (en)	2017-10-10	2023-05-30	Bristol-Myers Squibb Company	Cyclic dinucleotides as anticancer agents
IL315737A (en)	2017-10-13	2024-11-01	Harpoon Therapeutics Inc	B cell maturation antigen binding proteins
CN111406063B (en)	2017-10-16	2023-09-15	百时美施贵宝公司	Cyclic dinucleotides as anticancer agents
WO2019089921A1 (en)	2017-11-01	2019-05-09	Bristol-Myers Squibb Company	Immunostimulatory agonistic antibodies for use in treating cancer
CN111527084B (en)	2017-11-06	2023-07-18	百时美施贵宝公司	Isofuranone compounds useful as HPK1 inhibitors
IL315310A (en)	2017-12-26	2024-10-01	Kymera Therapeutics Inc	IRAK joints and used in them
EP3732198A1 (en)	2017-12-27	2020-11-04	Bristol-Myers Squibb Company	Anti-cd40 antibodies and uses thereof
US11447449B2 (en)	2018-01-05	2022-09-20	Bristol-Myers Squibb Company	Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US12129297B2 (en)	2018-01-12	2024-10-29	Bristol-Myers Squibb Company	Antibodies against TIM3 and uses thereof
US11512080B2 (en)	2018-01-12	2022-11-29	Kymera Therapeutics, Inc.	CRBN ligands and uses thereof
US11485743B2 (en)	2018-01-12	2022-11-01	Kymera Therapeutics, Inc.	Protein degraders and uses thereof
EP3743095A1 (en)	2018-01-26	2020-12-02	Celldex Therapeutics, Inc.	Methods of treating cancer with dendritic cell mobilizing agents
WO2019148132A1 (en)	2018-01-29	2019-08-01	Merck Patent Gmbh	Gcn2 inhibitors and uses thereof
MX2020007797A (en)	2018-01-29	2020-09-18	Merck Patent Gmbh	Gcn2 inhibitors and uses thereof.
US10519187B2 (en)	2018-02-13	2019-12-31	Bristol-Myers Squibb Company	Cyclic dinucleotides as anticancer agents
WO2019165315A1 (en)	2018-02-23	2019-08-29	Syntrix Biosystems Inc.	Method for treating cancer using chemokine antagonists alone or in combination
GB201803226D0 (en) *	2018-02-28	2018-04-11	Ultrahuman Twelve Ltd	CSF1R Binding agents
EP3758736B1 (en) *	2018-03-02	2024-05-01	The United States of America, as represented by The Secretary, Department of Health and Human Services	Il-34 for use in a method of treating retinal inflammation and neurodegeneration
AU2019230001A1 (en) *	2018-03-05	2020-09-24	Massachusetts Eye And Ear Infirmary	Amelioration of autoimmune uveitis through blockade of CSF1R
ES2980374T3 (en)	2018-03-08	2024-10-01	Bristol Myers Squibb Co	Cyclic dinucleotides as anticancer agents
EP3768716A1 (en)	2018-03-21	2021-01-27	Five Prime Therapeutics, Inc.	Antibodies binding to vista at acidic ph
PE20210665A1 (en)	2018-03-23	2021-03-31	Bristol Myers Squibb Co	ANTIBODIES AGAINST MICA AND / OR MICB AND ITS USES
CN112154153A (en)	2018-03-28	2020-12-29	百时美施贵宝公司	Interleukin-2/Interleukin-2 receptor alpha fusion proteins and methods of use
SG11202009839PA (en)	2018-04-12	2020-11-27	Bristol Myers Squibb Co	Anticancer combination therapy with cd73 antagonist antibody and pd-1/pd-l1 axis antagonist antibody
CN112292128A (en)	2018-04-16	2021-01-29	阿瑞斯医疗有限公司	EP4 inhibitors and uses thereof
US12037323B2 (en)	2018-05-03	2024-07-16	Bristol-Myers Squibb Company	Uracil derivatives as Mer-AXL inhibitors
US11180531B2 (en)	2018-06-22	2021-11-23	Bicycletx Limited	Bicyclic peptide ligands specific for Nectin-4
JP7432532B2 (en)	2018-06-27	2024-02-16	ブリストル－マイヤーズスクイブカンパニー	Substituted naphthyridinone compounds useful as T cell activators
DK3814347T3 (en)	2018-06-27	2023-08-07	Bristol Myers Squibb Co	NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS
WO2020010177A1 (en)	2018-07-06	2020-01-09	Kymera Therapeutics, Inc.	Tricyclic crbn ligands and uses thereof
BR112020027095A2 (en)	2018-07-09	2021-03-30	Five Prime Therapeutics, Inc.	ILT4 BINDING ANTIBODIES
JP2022513421A (en)	2018-07-11	2022-02-08	ファイブプライムセラピューティクス，インコーポレイテッド	Antibodies that bind VISTA at acidic pH
AU2019306582B2 (en)	2018-07-18	2023-03-16	Arcus Biosciences, Inc.	Solid forms of an azolopyrimidine compound
WO2020023355A1 (en)	2018-07-23	2020-01-30	Bristol-Myers Squibb Company	Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2020023356A1 (en)	2018-07-23	2020-01-30	Bristol-Myers Squibb Company	Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US10959986B2 (en)	2018-08-29	2021-03-30	Bristol-Myers Squibb Company	Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US11253525B2 (en)	2018-08-29	2022-02-22	Bristol-Myers Squibb Company	Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2020051424A1 (en)	2018-09-07	2020-03-12	Pic Therapeutics	Eif4e inhibitors and uses thereof
US12195544B2 (en)	2018-09-21	2025-01-14	Harpoon Therapeutics, Inc.	EGFR binding proteins and methods of use
MX2021003554A (en)	2018-09-25	2021-05-27	Harpoon Therapeutics Inc	DLL3-BINDING PROTEINS AND METHODS OF USE.
TW202035445A (en)	2018-10-10	2020-10-01	美商帝洛斯療法股份有限公司	Anti-lap antibody variants and uses thereof
PE20211284A1 (en)	2018-11-16	2021-07-19	Bristol Myers Squibb Co	ANTI-NKG2A ANTIBODIES AND USES OF THEM
CN113382998A (en)	2018-11-16	2021-09-10	艾库斯生物科学有限公司	Inhibitors of ARG1 and/or ARG2
AU2019389174A1 (en)	2018-11-30	2021-07-01	Kymera Therapeutics, Inc.	Irak degraders and uses thereof
WO2020123444A1 (en)	2018-12-11	2020-06-18	Celldex Therapeutics, Inc.	Methods of using cd27 antibodies as conditioning treatment for adoptive cell therapy
EP3670659A1 (en)	2018-12-20	2020-06-24	Abivax	Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
EA202192555A1 (en)	2019-03-19	2021-11-25	Фундасио Привада Институт Д'Инвестигасио Онколохика Де Валь Эброн	COMBINATION THERAPY FOR CANCER TREATMENT
CA3135487A1 (en)	2019-03-29	2020-10-08	Arcus Biosciences, Inc.	Treatment of cancer utilizing an identified adenosine fingerprint
EP3946462A1 (en)	2019-04-02	2022-02-09	BicycleTX Limited	Bicycle toxin conjugates and uses thereof
BR112021019748A2 (en)	2019-04-05	2021-12-07	Kymera Therapeutics Inc	Stat degraders and their uses
WO2020231713A1 (en)	2019-05-13	2020-11-19	Bristol-Myers Squibb Company	AGONISTS OF ROR GAMMAt
WO2020231766A1 (en)	2019-05-13	2020-11-19	Bristol-Myers Squibb Company	AGONISTS OF ROR GAMMAt
EP3976192A1 (en)	2019-05-31	2022-04-06	Ikena Oncology, Inc.	Tead inhibitors and uses thereof
WO2021026179A1 (en)	2019-08-06	2021-02-11	Bristol-Myers Squibb Company	AGONISTS OF ROR GAMMAt
WO2021024020A1 (en)	2019-08-06	2021-02-11	Astellas Pharma Inc.	Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
AR119821A1 (en)	2019-08-28	2022-01-12	Bristol Myers Squibb Co	SUBSTITUTED PYRIDOPYRIMIDINOL COMPOUNDS USEFUL AS T-CELL ACTIVATORS
WO2021050964A1 (en)	2019-09-13	2021-03-18	Nimbus Saturn, Inc.	Hpk1 antagonists and uses thereof
CN114729043A (en)	2019-09-19	2022-07-08	百时美施贵宝公司	Antibodies that bind to VISTA at acidic pH
US11548870B2 (en)	2019-11-19	2023-01-10	Bristol-Myers Squibb Company	Compounds useful as inhibitors of helios protein
AU2020394424A1 (en)	2019-11-26	2022-06-16	Ikena Oncology, Inc.	Polymorphic carbazole derivatives and uses thereof
CN115151306A (en)	2019-11-26	2022-10-04	百时美施贵宝公司	Salts/co-crystals of (R) -N- (4-chlorophenyl) -2- ((1S, 4S) -4- (6-fluoroquinolin-4-yl) cyclohexyl) propanamide
EP4076524A4 (en)	2019-12-17	2023-11-29	Kymera Therapeutics, Inc.	Irak degraders and uses thereof
US11779578B2 (en)	2019-12-17	2023-10-10	Kymera Therapeutics, Inc.	IRAK degraders and uses thereof
IL294270A (en)	2019-12-23	2022-08-01	Bristol Myers Squibb Co	Substituted piperazine derivatives are useful as t-cell activators
US20230086933A1 (en)	2019-12-23	2023-03-23	Bristol-Myers Squibb Company	Substituted heteroaryl compounds useful as t cell activators
CA3162985A1 (en)	2019-12-23	2021-07-01	Upender Velaparthi	Substituted quinazolinyl compounds useful as t cell activators
CN115297931A (en)	2019-12-23	2022-11-04	凯麦拉医疗公司	SMARCA degraders and their uses
AR120823A1 (en)	2019-12-23	2022-03-23	Bristol Myers Squibb Co	SUBSTITUTED BICYCLIC COMPOUNDS USEFUL AS T-CELL ACTIVATORS
CN115103841B (en)	2019-12-23	2024-12-27	百时美施贵宝公司	Substituted quinolinone piperazine compounds useful as T cell activators
BR112022013424A2 (en)	2020-01-06	2022-12-13	Hifibio Hk Ltd	ANTI-TNFR2 ANTIBODY AND ITS USES
BR112022013494A2 (en)	2020-01-07	2022-09-13	Hifibio Hk Ltd	ANTI-GALECTIN-9 ANTIBODY AND USES THEREOF
TW202146393A (en)	2020-03-03	2021-12-16	美商皮克醫療公司	Eif4e inhibitors and uses thereof
US20230140384A1 (en)	2020-03-09	2023-05-04	Bristol-Myers Squibb Company	Antibodies to cd40 with enhanced agonist activity
CA3171258A1 (en)	2020-03-19	2021-09-23	Nan JI	Mdm2 degraders and uses thereof
MX2022011534A (en)	2020-03-19	2022-10-13	Arcus Biosciences Inc	TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS HIF-2ALFA INHIBITORS.
TW202140441A (en)	2020-03-23	2021-11-01	美商必治妥美雅史谷比公司	Substituted oxoisoindoline compounds
WO2021207449A1 (en)	2020-04-09	2021-10-14	Merck Sharp & Dohme Corp.	Affinity matured anti-lap antibodies and uses thereof
TWI799840B (en)	2020-04-30	2023-04-21	美商美國禮來大藥廠	Compounds and methods targeting interleukin-34
WO2021231732A1 (en)	2020-05-15	2021-11-18	Bristol-Myers Squibb Company	Antibodies to garp
AR122493A1 (en)	2020-06-02	2022-09-14	Arcus Biosciences Inc	ANTI-TIGIT ANTIBODIES
TW202210483A (en)	2020-06-03	2022-03-16	美商凱麥拉醫療公司	Crystalline forms of irak degraders
US20230250110A1 (en)	2020-06-03	2023-08-10	Kymera Therapeutics, Inc.	Deuterated irak degraders and uses thereof
AU2021292195A1 (en)	2020-06-17	2023-01-05	Arcus Biosciences, Inc.	Crystalline forms of a CD73 inhibitor and uses thereof
KR20230035576A (en)	2020-07-07	2023-03-14	비온테크 에스이	RNA for the treatment of HPV-positive cancer
WO2022027058A1 (en)	2020-07-30	2022-02-03	Kymera Therapeutics, Inc.	Methods of treating mutant lymphomas
IL300537A (en)	2020-08-10	2023-04-01	Gv20 Therapeutics Llc	Compositions and methods for treating autoimmune diseases and cancers by targeting igsf8
US20240240255A1 (en)	2020-08-17	2024-07-18	Bicycletx Limited	Bicycle conjugates specific for nectin-4 and uses thereof
WO2022120353A1 (en)	2020-12-02	2022-06-09	Ikena Oncology, Inc.	Tead inhibitors and uses thereof
CA3200814A1 (en)	2020-12-02	2022-06-09	Alfredo C. Castro	Tead inhibitors and uses thereof
TW202245808A (en)	2020-12-21	2022-12-01	德商拜恩迪克公司	Therapeutic rna for treating cancer
WO2022135667A1 (en)	2020-12-21	2022-06-30	BioNTech SE	Therapeutic rna for treating cancer
WO2022135666A1 (en)	2020-12-21	2022-06-30	BioNTech SE	Treatment schedule for cytokine proteins
JP2024503300A (en)	2020-12-30	2024-01-25	カイメラセラピューティクス，インコーポレイテッド	IRAK decomposers and their uses
US20240325554A1 (en)	2021-01-11	2024-10-03	Bicycle TX Limited	Methods for treating cancer
CA3206499A1 (en)	2021-02-02	2022-08-11	Liminal Biosciences Limited	Gpr84 antagonists and uses thereof
CA3206501A1 (en)	2021-02-02	2022-08-11	Shaun Abbott	Gpr84 antagonists and uses thereof
US20240109899A1 (en)	2021-02-04	2024-04-04	Bristol-Myers Squibb Company	Benzofuran compounds as sting agonists
KR20230145446A (en)	2021-02-15	2023-10-17	카이메라 쎄라퓨틱스 인코포레이티드	IRAK4 degrader and its uses
CA3207049A1 (en)	2021-02-15	2022-08-18	Jared Gollob	Irak4 degraders and uses thereof
US11926625B2 (en)	2021-03-05	2024-03-12	Nimbus Saturn, Inc.	HPK1 antagonists and uses thereof
US11918582B2 (en)	2021-03-15	2024-03-05	Rapt Therapeutics, Inc.	Pyrazole pyrimidine compounds and uses thereof
US12071442B2 (en)	2021-03-29	2024-08-27	Nimbus Saturn, Inc.	Substituted pyrrolo[3,4-c]pyridines as HPK1 antagonists
US20240376224A1 (en)	2021-04-02	2024-11-14	The Regents Of The University Of California	Antibodies against cleaved cdcp1 and uses thereof
BR112023020410A2 (en)	2021-04-05	2023-11-28	Bristol Myers Squibb Co	OXOISOINDOLINE COMPOUNDS REPLACED BY PYRIDINILE FOR CANCER TREATMENT
JP2024515243A (en)	2021-04-06	2024-04-08	ブリストル－マイヤーズスクイブカンパニー	Pyridinyl-substituted oxoisoindoline compounds
IL307673A (en)	2021-04-16	2023-12-01	Ikena Oncology Inc	Mek inhibitors and uses thereof
AR125798A1 (en)	2021-05-07	2023-08-16	Kymera Therapeutics Inc	CDK2 DEGRADERS AND USES THEREOF
EP4337763A1 (en)	2021-05-10	2024-03-20	Institut Curie	Methods for the treatment of cancer, inflammatory diseases and autoimmune diseases
CN117321206A (en)	2021-05-17	2023-12-29	诺格拉制药有限公司	IL-34 antisense agents and methods of use thereof
EP4341262A1 (en)	2021-05-21	2024-03-27	Arcus Biosciences, Inc.	Axl inhibitor compounds
CN117295741A (en)	2021-05-21	2023-12-26	艾库斯生物科学有限公司	AXL compounds
EP4370552A1 (en)	2021-07-13	2024-05-22	BioNTech SE	Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
IL310924A (en)	2021-08-25	2024-04-01	Pic Therapeutics Inc	EIF4E inhibitors and their uses
CN118019739A (en)	2021-08-25	2024-05-10	皮克医疗公司	EIF4E inhibitors and uses thereof
TW202333802A (en)	2021-10-11	2023-09-01	德商拜恩迪克公司	Therapeutic rna for lung cancer
CA3236265A1 (en)	2021-10-29	2023-05-04	William Leong	Irak4 degraders and synthesis thereof
US11976114B2 (en)	2021-10-29	2024-05-07	Eli Lilly And Company	Compounds and methods targeting interleukin-34
AU2022376961A1 (en)	2021-10-29	2024-05-16	Arcus Biosciences, Inc.	Inhibitors of hif-2alpha and methods of use thereof
TW202334210A (en) *	2021-10-29	2023-09-01	美商美國禮來大藥廠	Compounds and methods targeting interleukin-34
WO2023114984A1 (en)	2021-12-17	2023-06-22	Ikena Oncology, Inc.	Tead inhibitors and uses thereof
JP2025504059A (en)	2022-01-31	2025-02-06	カイメラセラピューティクス，インコーポレイテッド	IRAK Degrader and its Use
JP2025503312A (en)	2022-02-01	2025-01-30	アルビナス・オペレーションズ・インコーポレイテッド	DGK-TARGETING COMPOUNDS AND USES THEREOF
WO2023173057A1 (en)	2022-03-10	2023-09-14	Ikena Oncology, Inc.	Mek inhibitors and uses thereof
WO2023173053A1 (en)	2022-03-10	2023-09-14	Ikena Oncology, Inc.	Mek inhibitors and uses thereof
WO2023211889A1 (en)	2022-04-25	2023-11-02	Ikena Oncology, Inc.	Polymorphic compounds and uses thereof
AU2023264591A1 (en)	2022-05-02	2024-11-07	Arcus Biosciences, Inc.	Anti-tigit antibodies and uses of the same
WO2023230205A1 (en)	2022-05-25	2023-11-30	Ikena Oncology, Inc.	Mek inhibitors and uses thereof
US20240124490A1 (en)	2022-07-15	2024-04-18	Arcus Biosciences, Inc.	Inhibitors of hpk1 and methods of use thereof
WO2024020034A1 (en)	2022-07-20	2024-01-25	Arcus Biosciences, Inc.	Cbl-b inhibitors and methods of use thereof
WO2024028365A1 (en)	2022-08-02	2024-02-08	Liminal Biosciences Limited	Substituted pyridone gpr84 antagonists and uses thereof
TW202415650A (en)	2022-08-02	2024-04-16	英商利米那生物科技有限公司	Aryl-triazolyl and related gpr84 antagonists and uses thereof
TW202416950A (en)	2022-08-02	2024-05-01	英商利米那生物科技有限公司	Heteroaryl carboxamide and related gpr84 antagonists and uses thereof
WO2024036100A1 (en)	2022-08-08	2024-02-15	Bristol-Myers Squibb Company	Substituted tetrazolyl compounds useful as t cell activators
WO2024036101A1 (en)	2022-08-09	2024-02-15	Bristol-Myers Squibb Company	Tertiary amine substituted bicyclic compounds useful as t cell activators
WO2024081385A1 (en)	2022-10-14	2024-04-18	Arcus Biosciences, Inc.	Hpk1 inhibitors and methods of use thereof
WO2024086718A1 (en)	2022-10-20	2024-04-25	Arcus Biosciences, Inc.	Lyophilized formulations of cd73 compounds
US20240208961A1 (en)	2022-11-22	2024-06-27	PIC Therapeutics, Inc.	Eif4e inhibitors and uses thereof
WO2024126457A1 (en)	2022-12-14	2024-06-20	Astellas Pharma Europe Bv	Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors
WO2024233360A1 (en)	2023-05-05	2024-11-14	Arcus Biosciences, Inc.	Cbl-b inhibitors and methods of use thereof
EP4511371A1 (en)	2023-05-08	2025-02-26	Bristol-Myers Squibb Company	Substituted phenyl oxazolone compounds
WO2024243502A1 (en)	2023-05-25	2024-11-28	Arcus Biosciences, Inc.	Cbl-b inhibitors and methods of use thereof
WO2024249540A1 (en)	2023-05-31	2024-12-05	Bristol-Myers Squibb Company	Substituted oxazolone compound for decreasing levels of ikzf1-4 proteins
WO2024254227A1 (en)	2023-06-07	2024-12-12	Bristol-Myers Squibb Company	Spirocyclic substituted oxoisoindolinyl piperidine-2,6-dione compound
WO2024263853A1 (en)	2023-06-23	2024-12-26	Bristol-Myers Squibb Company	Substituted oxoisoindolinyl piperidine-2,6-dione compound as anticancer agent
WO2025030002A2 (en)	2023-08-02	2025-02-06	Arvinas Operations, Inc.	Dgk targeting compounds and uses thereof
US12176075B1 (en) *	2023-11-14	2024-12-24	United Arab Emirates University	Method of matching conformers of different molecules

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2009112245A1 (en) *	2008-03-14	2009-09-17	Transgene S.A.	Antibody against the csf-1 r
WO2011140249A2 (en) *	2010-05-04	2011-11-10	Five Prime Therapeutics, Inc.	Antibodies that bind csf1r

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR080698A1 (en) *	2010-04-01	2012-05-02	Imclone Llc	ANTIBODY OR FRAGMENT OF THE SAME THAT SPECIFICALLY LINKS THE VARIOUS OF HUMAN CSF -1R, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, ITS USE FOR THE MANUFACTURE OF A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF CANCER AND METHOD TO DETERMINE IF A BASED SUBJECT MATTER AND

2013
- 2013-02-06 MX MX2014008961A patent/MX2014008961A/en unknown
- 2013-02-06 WO PCT/US2013/024998 patent/WO2013119716A1/en active Application Filing
- 2013-02-06 RU RU2014136332A patent/RU2014136332A/en not_active Application Discontinuation
- 2013-02-06 CA CA2861122A patent/CA2861122A1/en not_active Abandoned
- 2013-02-06 JP JP2014555859A patent/JP6416630B2/en not_active Expired - Fee Related
- 2013-02-06 EP EP13746304.8A patent/EP2812355A4/en not_active Withdrawn
- 2013-02-06 CN CN201380008292.7A patent/CN104093740B/en not_active Expired - Fee Related
- 2013-02-06 BR BR112014018961A patent/BR112014018961A8/en not_active IP Right Cessation
- 2013-02-06 KR KR1020147024752A patent/KR20140127855A/en not_active Application Discontinuation
2015
- 2015-04-01 HK HK15103325.3A patent/HK1202879A1/en not_active IP Right Cessation
2017
- 2017-06-13 JP JP2017116326A patent/JP2017200482A/en active Pending

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2009112245A1 (en) *	2008-03-14	2009-09-17	Transgene S.A.	Antibody against the csf-1 r
WO2011140249A2 (en) *	2010-05-04	2011-11-10	Five Prime Therapeutics, Inc.	Antibodies that bind csf1r

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DROIN NATHALIE ET AL: "Editorial: CSF1R, CSF-1, and IL-34, a menage a trois conserved across vertebrates", JOURNAL OF LEUKOCYTE BIOLOGY, FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY, US, vol. 87, no. 5, 1 May 2010 (2010-05-01), pages 745 - 747, XP009138538, ISSN: 0741-5400, DOI: 10.1189/JLB.1209780 *
HAISHAN LIN ET AL: "Discovery of a cytokine and its receptor by functional screening of the extracellular proteome", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, US, vol. 320, no. 5877, 9 May 2008 (2008-05-09), pages 807 - 811, XP002638423, ISSN: 1095-9203, DOI: 10.1126/SCIENCE.1154370 *
See also references of WO2013119716A1 *
T CHIHARA ET AL: "IL-34 and M-CSF share the receptor Fms but are not identical in biological activity and signal activation", CELL DEATH AND DIFFERENTIATION, vol. 17, no. 12, 1 December 2010 (2010-12-01), pages 1917 - 1927, XP055036155, ISSN: 1350-9047, DOI: 10.1038/cdd.2010.60 *

Also Published As

Publication number	Publication date
HK1202879A1 (en)	2015-10-09
CN104093740B (en)	2018-01-09
MX2014008961A (en)	2014-10-14
BR112014018961A8 (en)	2017-07-11
JP2015510510A (en)	2015-04-09
JP2017200482A (en)	2017-11-09
WO2013119716A8 (en)	2014-08-07
CN104093740A (en)	2014-10-08
EP2812355A1 (en)	2014-12-17
WO2013119716A1 (en)	2013-08-15
JP6416630B2 (en)	2018-10-31
KR20140127855A (en)	2014-11-04
RU2014136332A (en)	2016-03-27
CA2861122A1 (en)	2013-08-15
BR112014018961A2 (en)	2017-06-20

Publication	Publication Date	Title
EP2812355A4 (en)	2016-03-02	COMPOSITIONS AND METHODS OF USING CSF1R INHIBITORS
EP2773651A4 (en)	2015-08-12	SPECIFIC B7-H4-ISOLATED COMPOSITIONS AND METHODS OF USE THEREOF
EP2912178A4 (en)	2016-05-25	SUPER-ACTIVATORS AND METHODS OF USE THEREOF
EP2903637A4 (en)	2016-10-19	COMPOSITIONS AND METHODS OF IMMUNOTHERAPY
EP2579831A4 (en)	2015-11-18	DISTRIBUTOR AND METHODS OF USE
EP2673381A4 (en)	2014-10-15	BIOSONS AND METHODS OF USE THEREOF
EP2920319A4 (en)	2016-07-06	SITE SPECIFIC ENZYMES AND METHODS OF USE THEREOF
EP2667889A4 (en)	2014-08-06	WNT COMPOSITIONS AND METHODS OF USE THEREOF
EP2619184A4 (en)	2014-05-14	DEUBIQUITINASE INHIBITORS AND METHODS OF USE
EP2938189A4 (en)	2015-11-11	CONTROLLED RELEASE COMPOSITIONS AND METHODS OF USE
EP2836218A4 (en)	2015-10-21	PREBIOTIC COMPOSITIONS AND METHODS OF USE
EP2914575A4 (en)	2016-11-09	INHIBITORS OF PLASMINOGEN ACTIVATOR 1 AND METHODS OF USE
EP2838954A4 (en)	2015-11-25	ADHESIVE COMPOSITIONS AND METHODS
EP2670866A4 (en)	2015-09-02	BIOMARKERS AND METHODS OF USE
EP2763597A4 (en)	2015-04-29	SUTURE ANCHORS AND METHODS OF USE
ME03766B (en)	2021-04-20	CERTAIN AMINO-PYRIMIDINES, THEIR COMPOSITIONS, AND METHODS OF THEIR USE
EP2751086A4 (en)	2015-09-16	KYNURENIN-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF
EP2964235A4 (en)	2016-11-09	ANTIMICROBIAL-ANTIBIOFILM COMPOSITIONS AND METHODS OF USE
EP2849788A4 (en)	2015-10-21	METHODS AND USE OF SUBTILISINE / KEXINE 9 PROPYTEIN CONVERTASE INHIBITORS (PCSK9)
EP2726477A4 (en)	2015-08-26	SMALL MOLECULE CD38 INHIBITORS AND METHODS OF USE
EP2833879A4 (en)	2016-03-02	KYNURENIN-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF
EP2895181A4 (en)	2016-03-30	TOPICAL COMPOSITIONS AND METHODS OF USE
EP2750677A4 (en)	2015-05-27	KYNURENIN-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF
EP2884984A4 (en)	2016-03-16	COMPOSITIONS AND THERAPEUTIC METHODS
EP2701512A4 (en)	2014-11-26	INHIBITORS OF ALDOSTERONE SYNTHASE

Legal Events

Date	Code	Title	Description
2014-11-14	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2014-12-17	17P	Request for examination filed	Effective date: 20140908
2014-12-17	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2014-12-17	AX	Request for extension of the european patent	Extension state: BA ME
2015-05-13	DAX	Request for extension of the european patent (deleted)
2015-12-23	RIC1	Information provided on ipc code assigned before grant	Ipc: C07K 16/24 20060101AFI20151113BHEP Ipc: A61K 39/395 20060101ALI20151113BHEP Ipc: A61P 19/02 20060101ALI20151113BHEP
2016-03-02	RA4	Supplementary search report drawn up and despatched (corrected)	Effective date: 20160128
2016-03-02	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 39/395 20060101ALI20160122BHEP Ipc: A61P 19/02 20060101ALI20160122BHEP Ipc: C07K 16/24 20060101AFI20160122BHEP
2016-10-05	R17P	Request for examination filed (corrected)	Effective date: 20140908
2017-03-24	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2017-04-26	17Q	First examination report despatched	Effective date: 20170327
2019-02-22	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2019-03-27	18D	Application deemed to be withdrawn	Effective date: 20181027